The strength of in-vivo OCT imaging in mice lies not only in detailing the foci of the lesions within the retinal layers, but in monitoring tumor growth longitudinally with documentation of the invasion or disruption of the inner and outer retina.
Indianapolis, In. (PRWEB) August 28, 2013
Researchers at the Eugene and Marilyn Glick Eye Institute at the Indiana University School of Medicine have been successful in visualizing retinoblastoma tumors in Tag-RB mice as early as 8 weeks of age using OCT technology. This is one week earlier than reported in the literature.1,2. By 10 weeks of age, retinoblastoma tumors in this transgenic mouse model were clearly delineated within the inner nuclear layer. The Phoenix Research Laboratories Image-Guided OCT facilitates in-vivo imaging of the tumors in histologic detail.
“The strength of in-vivo OCT imaging in mice lies not only in detailing the foci of the lesions within the retinal layers, but in the ability to monitor tumor growth longitudinally with documentation of the invasion or disruption of the inner and outer retina.” notes Tim Corson, PhD, Assistant Professor at the Glick Eye Institute, Indianapolis.
Retinoblastoma is the most common eye malignancy in children, usually affecting those younger than age 5. Early detection is the key to successful treatment of this blinding and potentially lethal cancer. Mouse models of retinoblastoma have provided insights into the development and treatment of tumors in the retina, as well the genetic pattern of inheritance of other cancers.
The Phoenix Image-Guided OCT delivers longitudinal resolution under 2 microns and enables precise OCT scan placement by providing a guide beam in the bright field image. Even small lesions not visible in the bright field image can be detected by OCT, easily scanned and their location referenced.
“We are excited and pleased by the contribution the Phoenix Image-Guided OCT System is making in groundbreaking research such as this retinoblastoma study,” said Bert Massie, PhD, Chairman and CEO of Phoenix Research Labs. “The power of in vivo OCT imaging is fueling earlier detection discoveries while contributing to the understanding of tumorigenesis, morphology and treatment efficacies. We are honored to be playing a role in such impactful scientific advancements.”
About Phoenix Research Labs
Phoenix Research Labs is an animal eye research company focused on developing innovative technologies to advance the study of eye diseases. The Phoenix product line includes the Micron IV Retinal Imaging Microscope, Image-Guided OCT System, Ganzfeld ERG System, Image-Guided Focal ERG System, Image-Guided Laser System and Anterior Segment Image System. With systems located in the US, Europe, Asia and Latin America, Phoenix Research Labs has a global presence in the world ophthalmology research effort. Incorporated in 2008 by Dr. Bert Massie, the company is located in Pleasanton, CA. For more information visit http://www.phoenixreslabs.com.
1. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1808-14. In vivo three-dimensional high-resolution imaging of rodent retina with spectral-domain optical coherence tomography. Ruggeri M, Wehbe H, Jiao S, Gregori G, Jockovich ME, Hackam A, Duan Y, Puliafito CA.
2. Opt Express. 2009 Mar 2;17(5):4074-83. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, Murray TG, Puliafito CA.
Vicki Hermansen, Director, Marketing & Communications
Eugene and Marilyn Glick Eye Institute
IU School of Medicine Department of Ophthalmology
Melody Bertolucci, Director of Marketing
Phoenix Research Labs